Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Quercetin

Quercetin Dihydrate / Phytosome · also known as Quercetin, Quercetin phospholipid complex

In experimental models, quercetin can inhibit mast cell degranulation and influence NF-κB- and SIRT1-related signaling. Human evidence is limited, and a senolytic effect of quercetin alone has not been established.

Typical dose: Phospholipid form 250–500 mg/day; standard form 500–1000 mg/day (taken with a meal that contains fat)
Absorption and forms: Oral absorption of quercetin dihydrate is very low, and the exact figure varies by study. The phospholipid complex has roughly a 20-fold absorption advantage, but that figure comes from a specific comparison of total quercetin exposure and does not mean a 20-fold increase in the free, active parent compound.

Clinical uses and human evidence

Allergic rhinitis

BeneficialGrade B · Moderate evidence
Studies (1)
  1. Yamada 2022 · Eur Rev Med Pharmacol Sci · RCT · n=66 — Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study

High blood pressure

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Arabi 2023 · Phytother Res · systematic review — The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials

Endurance performance

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Kressler 2011 · Med Sci Sports Exerc · meta-analysis · n=254 — Quercetin and endurance exercise capacity: a systematic review and meta-analysis

Blood sugar and insulin resistance

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Arabi 2023 · Phytother Res · systematic review — The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials

High LDL cholesterol

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Arabi 2023 · Phytother Res · systematic review — The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials

High triglycerides

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Arabi 2023 · Phytother Res · systematic review — The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials

Inflammation markers (such as CRP)

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Arabi 2023 · Phytother Res · systematic review — The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials

Colds: prevention and duration

No benefitGrade B · Moderate evidence
Studies (1)
  1. Heinz 2010 · Pharmacol Res · RCT · n=1002 — Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial

Mechanisms of action

Mast cell membrane stabilization and degranulation blockade

★★★☆☆Mechanism evidence: grade CPrimary target

Quercetin can inhibit mast cell degranulation and reduce histamine release in experimental models. Some allergy symptoms improved in human trials, but these trials did not directly confirm mast-cell stabilization in humans, and symptom changes cannot stand in for measuring the mechanism.

References (2)
  1. Ding et al. 2019 · Mouse and cell experiments: quercetin reduced histamine release and mast cell degranulation in mice; the calcium signaling mechanism has mainly been studied in cells
  2. Yamada et al. 2022 · Randomized human trial: some allergy symptoms improved, but mast-cell stabilization in humans was not directly confirmed

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★★☆☆Mechanism evidence: grade CSecondary target

Quercetin can inhibit NF-κB signaling in some animal and cell models, reducing p65 nuclear translocation. After usual oral dosing, the circulating form is mainly conjugated metabolites. There is no direct evidence on whether p65 nuclear translocation is blocked in humans.

References (2)
  1. Li et al. 2016 · Oral dosing in mice: reduced p65 nuclear translocation and IκBα degradation in a liver fibrosis model
  2. Nair et al. 2006 · In-vitro study in human-derived cells: quercetin modulated NF-κB-related responses; some experiments used relatively high concentrations

Sirtuin-dependent protein deacetylase activation

★☆☆☆☆Mechanism evidence: grade CSecondary target

Animal models suggest quercetin may modulate SIRT1 indirectly. The claim that it directly activates SIRT1 allosterically is disputed because the results depend on the assay method and substrate. Its effect at usual human doses has not been confirmed.

References (2)
  1. Hu et al. 2020 · Diabetic mouse experiment: high-dose quercetin was accompanied by higher SIRT1 expression in brain tissue
  2. 2018 · In-vitro study: SIRT1 assays with flavonoids are affected by fluorescence and substrate conditions

Apoptosis-driven clearance of senescent cells (senolytic activity)

★☆☆☆☆Mechanism evidence: grade DSecondary target

Studies pairing dasatinib with quercetin to clear senescent cells are still exploratory, and the results cannot be attributed to quercetin alone. The selective senolytic effect of quercetin alone comes mainly from cell experiments and has not been established.

References (2)
  1. Hickson et al. 2019 · Human uncontrolled pilot study: tissue senescence markers fell after dasatinib plus quercetin, and this cannot be attributed to quercetin alone
  2. Hohmann et al. 2019 · Cell and mouse experiments: quercetin reduced senescence markers in mouse lung; in cell experiments, quercetin by itself did not induce apoptosis

Safety and drug interactions

Use with caution in severe kidney impairment. In-vitro experiments show quercetin may inhibit CYP3A4, but this does not tell us how large any clinical interaction would be. If you take prescription drugs, check each one individually.

Inhibition of drug metabolism (CYP3A4 and others)

Inhibits CYP3A4. Each of these can inhibit the liver enzymes that metabolize drugs (mainly CYP3A4) or drug transporter proteins, raising blood levels of some prescription drugs.

Open in the interactive app ›